Peptide library · Weight loss / metabolic

Tirzepatide

A dual GIP and GLP-1 receptor agonist studied for significant weight loss, appetite regulation, and blood-sugar control. The GLP-class compound with the most human data behind it; typically started low and stepped up over several months to keep nausea manageable.

Also goes by

Tirzepatide · LY3298176 · Mounjaro · Zepbound · Tirz · GIP/GLP-1 dual agonist

Research-market price

~$4.50 /mg avg

observed range $0.87–$13.00/mg

Average across the research market as of 2026-07-19. Informational only — not a Blue Star price, and not an offer to sell.

Straight talk

Nausea and GI upset are common early — the slow titration is what limits them. This class carries a thyroid C-cell tumor warning: avoid with a personal or family history of medullary thyroid cancer or MEN 2.

Thinking about this one?

Don't figure it out alone. Talk it through with Daniel first — twenty years of firsthand experience, free, no strings. And if it makes your plan, the app tracks it: doses, draws, supplies, and the bloodwork to watch.

Educational information, not medical advice. Nothing here says this compound will treat, cure, or prevent anything. Talk to your physician.